Cytomx Lung Cancer Foundation And The Joan Gaeta Lung Cancer Equipment & Supplies
2 equipment items found
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX is developing CX-2009, a Probody drug conjugate (PDC) conjugated with DM4, a highly potent cytotoxic drug, targeting CD166, also known as ALCAM. CD166 is a molecule widely and highly expressed on solid tumor cells and previously considered “undruggable” given its expression on normal tissues. In preclinical studies, Probody drug conjugates targeting CD166, have led to ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX and AbbVie are co-developing CX-2029, a PDC directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors, as well as many normal tissues. CytomX is evaluating CX-2029 in a Phase 1/2 clinical trial as monotherapy. CD71 is an excellent “internalizer,” which has the potential to efficiently deliver toxin to tumor cells. ...